AstraZeneca Therapeutic Trials Show 77% Reduced Risk of Symptomatic Covid ...Middle East

Wilmington, DE…77% reduced risk of developing symptomatic COVID-19. First long-acting antibody combination to prevent COVID-19. Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca’s AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial’s primary endpoint. AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis. There were no cases of severe COVID-19 or COVID-19-related deaths in those tre

Read More Details
Finally We wish PressBee provided you with enough information of ( AstraZeneca Therapeutic Trials Show 77% Reduced Risk of Symptomatic Covid )

Also on site :

• Vacaville carjacking suspects arrested in Fairfield; suspect shot by police
• See photos of Jeff Bezos spanking bride-to-be Lauren Sánchez while lounging on $500M superyacht
• ‘80s Music Icon Poses Nude to Celebrate Her 67th Birthday